Grifols, S.A. (NASDAQ:GRFS) Shares Acquired by Blue Trust Inc.

Blue Trust Inc. raised its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 344.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,697 shares of the biotechnology company’s stock after acquiring an additional 6,740 shares during the quarter. Blue Trust Inc.’s holdings in Grifols were worth $65,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its holdings in shares of Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,527 shares during the last quarter. HighTower Advisors LLC boosted its position in Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 1,546 shares during the period. Signaturefd LLC boosted its position in Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares during the period. US Bancorp DE grew its stake in Grifols by 12.3% during the 3rd quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company’s stock worth $183,000 after buying an additional 2,256 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Grifols by 7.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 31,543 shares of the biotechnology company’s stock worth $280,000 after buying an additional 2,301 shares during the period.

Grifols Stock Down 0.3 %

Shares of Grifols stock opened at $7.43 on Tuesday. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $9.96. The business’s fifty day moving average price is $7.37 and its two-hundred day moving average price is $8.09. The company has a market capitalization of $5.11 billion, a P/E ratio of 6.35 and a beta of 0.40.

Wall Street Analyst Weigh In

GRFS has been the subject of several analyst reports. Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th. Morgan Stanley began coverage on shares of Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating for the company.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.